Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 346 AL 360

Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease

Park JJ, Choi SH, Kim S, Lee AY, Moon SY, Lee JH, Kwon JC, Park KW, Ku BD, Han HJ, Kim EJ, Shim YS.

Geriatr Gerontol Int. 2017 Oct;17(10):1661-1666. doi: 10.1111/ggi.12934. Epub 2016 Dec 9.

Molecular Diagnostics of Ageing and Tackling Age-related Disease

Timmons JA.

Trends Pharmacol Sci. 2017 Jan;38(1):67-80. doi: 10.1016/j.tips.2016.11.005. Epub 2016 Dec 12.

Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate Alzheimer's Disease in South Korea: RECAP Study Results

Lee KJ, Cho SJ, Kim BC, Park M, Lee JH.

Adv Ther. 2017 Feb;34(2):481-494. doi: 10.1007/s12325-016-0465-8. Epub 2016 Dec 20.

AVP-786 for the treatment of agitation in dementia of the Alzheimer's type

Garay RP, Grossberg GT.

Expert Opin Investig Drugs. 2017 Jan;26(1):121-132. doi: 10.1080/13543784.2017.1267726. Epub 2016 Dec 11.

The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis

Moraros J, Nwankwo C, Patten SB, Mousseau DD.

Depress Anxiety. 2017 Mar;34(3):217-226. doi: 10.1002/da.22584. Epub 2016 Dec 28.

Association between malnutrition and hyperhomocysteine in Alzheimer's disease patients and diet intervention of betaine

Sun J, Wen S, Zhou J, Ding S.

J Clin Lab Anal. 2017 Sep;31(5):e22090. doi: 10.1002/jcla.22090. Epub 2016 Nov 7.

Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease and Mild Cognitive Impairment: a Comprehensive Systematic Review and Meta-analysis

Kim BY, Lee SH, Graham PL, Angelucci F, Lucia A, Pareja-Galeano H, Leyhe T, Turana Y, Lee IR, Yoon JH, Shin JI.

Mol Neurobiol. 2017 Nov;54(9):7297-7311. doi: 10.1007/s12035-016-0192-9. Epub 2016 Nov 4.

Non human primate models for Alzheimer's disease-related research and drug discovery

Van Dam D, De Deyn PP.

Expert Opin Drug Discov. 2017 Feb;12(2):187-200. doi: 10.1080/17460441.2017.1271320. Epub 2016 Dec 25.

Management of LUTS in patients with dementia and associated disorders 

Averbeck MA, Altaweel W, Manu-Marin A, Madersbacher H.

Neurourol Urodyn. 2017 Feb;36(2):245-252. doi: 10.1002/nau.22928. Epub 2015 Nov 20.

Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease

Furukawa K, Tomita N, Uematsu D, Okahara K, Shimada H, Ikeda M, Matsui T, Kozaki K, Fujii M, Ogawa T, Umegaki H, Urakami K, Nomura H, Kobayashi N, Nakanishi A, Washimi Y, Yonezawa H, Takahashi S, Kubota M, Wakutani Y, Ito D, Sasaki T, Matsubara E, Une K, Ishiki A, Yahagi Y, Shoji M, Sato H, Terayama Y, Kuzuya M, Araki N, Kodama M, Yamaguchi T, Arai H.

Geriatr Gerontol Int. 2017 Feb;17(2):211-218. doi: 10.1111/ggi.12696. Epub 2015 Dec 29.

IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia

Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):106-112. doi: 10.1136/jnnp-2015-311486. Epub 2015 Sep 29.

Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes

Wang Q, Li WX, Dai SX, Guo YC, Han FF, Zheng JJ, Li GH, Huang JF.

J Alzheimers Dis. 2017;56(4):1525-1539. doi: 10.3233/JAD-161032.

MicroRNAs, Aging, Cellular Senescence, and Alzheimer's Disease

Reddy PH, Williams J, Smith F, Bhatti JS, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, Wang R, Manczak M, Yin X, Reddy AP.

Prog Mol Biol Transl Sci. 2017;146:127-171. doi: 10.1016/bs.pmbts.2016.12.009. Epub 2017 Feb 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias